Open AccessPB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s) -
Paul B.,
Liedtke M.,
Siegel D. S.,
Khouri J.,
Hillenglass J.,
Rifkin R.,
Gandhi M. D.,
Kin A.,
Levy M. Y.,
Mohrbacher A.,
Schmidt W.,
Silbermann R.,
Cottini F.,
Sborov D. W.,
Walker R.,
Murphy M.,
Gu L.,
Chen A.,
Rajakumaraswamy N.,
Usmani S. Z.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850880.23639.66
Subject(s) - daratumumab , tolerability , medicine , dexamethasone , bortezomib , multiple myeloma , carfilzomib , pomalidomide , oncology , proteasome inhibitor , pharmacology , cancer research , adverse effect